Clinical application of a new warfarin-dosing regimen based on the CYP2C9 and VKORC1 genotypes in atrial fibrillation patients | |
Jiang, Nian-Xin; Ge, Jun-Wei; Xian, Yu-Qiong; Huang, Shao-Ying; Li, Yan-Song | |
刊名 | BIOMEDICAL REPORTS
![]() |
2016 | |
卷号 | 4期号:4 |
关键词 | atrial fibrillation warfarin cytochrome P450 2C9 single nucleotide polymorphisms vitamin K epoxide reductase complex 1 |
ISSN号 | 2049-9434 |
URL标识 | 查看原文 |
语种 | 英语 |
内容类型 | 期刊论文 |
URI标识 | http://www.corc.org.cn/handle/1471x/3646736 |
专题 | 上海中医药大学 |
推荐引用方式 GB/T 7714 | Jiang, Nian-Xin,Ge, Jun-Wei,Xian, Yu-Qiong,et al. Clinical application of a new warfarin-dosing regimen based on the CYP2C9 and VKORC1 genotypes in atrial fibrillation patients[J]. BIOMEDICAL REPORTS,2016,4(4). |
APA | Jiang, Nian-Xin,Ge, Jun-Wei,Xian, Yu-Qiong,Huang, Shao-Ying,&Li, Yan-Song.(2016).Clinical application of a new warfarin-dosing regimen based on the CYP2C9 and VKORC1 genotypes in atrial fibrillation patients.BIOMEDICAL REPORTS,4(4). |
MLA | Jiang, Nian-Xin,et al."Clinical application of a new warfarin-dosing regimen based on the CYP2C9 and VKORC1 genotypes in atrial fibrillation patients".BIOMEDICAL REPORTS 4.4(2016). |
个性服务 |
查看访问统计 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论